• 
• 
• 
• 
• 
• 
• 

• 
• 
• 
• 

• 
• 
• 

• 
• 
• 
• 
• 

Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age

Giuliano F, Donatucci C, Montorsi F, Auerbach S, Karlin G, Norenberg C, Homering M, Segerson T, Eardley I; BJU International 2005; 95:110-116:

KEY WORDS: erectile dysfunction, elderly, oral PDE-5 inhibitors, placebo-controlled clinical trial

Vardenafil, a potent, selective inhibitor of phosphodiesterase-5 (PDE-5), is effective and generally well tolerated for treating ED, both in the general population with Erectile Disfunction (ED) and in those who are difficult to treat. It was suggested that the pharmacokinetics of vardenafil might differ among different age groups. The authors of this study assessed the efficacy and tolerability of vardenafil for treating ED in men of different ages in a retrospective analysis of two phase 3 trials.

• In a retrospective pooled subgroup analysis of randomized, double-blind, placebocontrolled studies, 1.385 men with ED from the general population were grouped by age (< 45, 45-64 and = 65 years) and received either placebo or vardenafil 5, 10 or 20 mg over 12 weeks. Efficacy variables included the erectile function (EF) domain score, diary response rates to questions on vaginal penetration and maintenance of erection and positive responses to the Global Assessment Question (GAQ).
• At 12 weeks the EF domain scores approached 20 with vardenafil and 14 with placebo in men aged = 65 years (P < 0.03 vardenafil 5 mg vs placebo, P < 0.001 vardenafil 10 and 20 mg vs placebo). The corresponding scores were 22 and 14 in men aged 45-64 years and up to 24 and 16 in those aged < 45 years (P < 0.03 vardenafil 5 mg vs placebo, P < 0.001 vardenafil 10 and 20 mg vs placebo).
• Vardenafil was an effective and generally well tolerated treatment for ED, irrespective of age

See the abstract

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15638906&dopt=Citation